BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38326567)

  • 21. Outcomes from hematopoietic stem cell transplantation following treosulfan-based conditioning: A clinical and pharmacokinetic analysis.
    Rosser SPA; Brewer A; Gabriel M; Wong M; Chung J; McLachlan AJ; Nath CE; Keogh SJ; Shaw PJ
    Pediatr Transplant; 2024 Jun; 28(4):e14780. PubMed ID: 38766999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome of treosulfan-based reduced-toxicity conditioning regimens for HSCT in high-risk patients with primary immune deficiencies.
    Haskoloğlu Ş; Köstel Bal S; İslamoğlu C; Altun D; Kendirli T; Doğu EF; İkincioğulları A
    Pediatr Transplant; 2018 Nov; 22(7):e13266. PubMed ID: 29992714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute toxicity and outcome among pediatric allogeneic hematopoietic transplant patients conditioned with treosulfan-based regimens.
    Huttunen P; Taskinen M; Vettenranta K
    Pediatr Hematol Oncol; 2020 Aug; 37(5):355-364. PubMed ID: 32166994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Augmented immunosuppression and PTCY-based haploidentical hematopoietic stem cell transplantation for thalassemia major.
    Vellaichamy Swaminathan V; Ravichandran N; Ramanan KM; Meena SK; Varla H; Ramakrishnan B; Jayakumar I; Uppuluri R; Raj R
    Pediatr Transplant; 2021 Mar; 25(2):e13893. PubMed ID: 33111490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience.
    Slatter MA; Rao K; Amrolia P; Flood T; Abinun M; Hambleton S; Nademi Z; Goulden N; Davies G; Qasim W; Gaspar HB; Cant A; Gennery AR; Veys P
    Blood; 2011 Apr; 117(16):4367-75. PubMed ID: 21325599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hematopoietic stem cell transplantation for B-thalassemia major with alemtuzumab.
    Sánchez LM; George A; Friend BD; Bhar S; Sasa G; Doherty EE; Craddock J; Steffin D; Salem B; Yassine K; Omer B; Martinez C; Leung K; Krance RA; John TD
    Pediatr Hematol Oncol; 2024 May; 41(4):260-272. PubMed ID: 38131101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN
    Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treosulfan Exposure Predicts Thalassemia-Free Survival in Patients with Beta Thalassemia Major Undergoing Allogeneic Hematopoietic Cell Transplantation.
    Pai AA; Mohanan E; Panetta JC; Kulkarni UP; Illangeswaran RSS; Balakrishnan B; Jayaraman A; Edison ES; Lakshmi KM; Devasia AJ; Fouzia NA; Korula A; Abraham A; George B; Srivastava A; Mathews V; Standing JF; Balasubramanian P
    Clin Pharmacol Ther; 2024 Jan; 115(1):116-125. PubMed ID: 37846495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fludarabine-based reduced toxicity yet myeloablative conditioning is effective and safe particularly in patients with high-risk thalassemia undergoing allogeneic transplantation.
    Sheth V; Grisariu S; Avni B; Stepensky P; Ashkenazi M; Shapira MY; Or R
    Pediatr Blood Cancer; 2018 Nov; 65(11):e27312. PubMed ID: 30070020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treosulfan-Based Conditioning Regimen in Haematopoietic Stem Cell Transplantation with TCRαβ/CD19 Depletion in Nijmegen Breakage Syndrome.
    Laberko A; Sultanova E; Gutovskaya E; Radygina S; Deripapa E; Kantulaeva A; Trakhtman P; Brilliantova V; Starichkova J; Shcherbina A; Maschan M; Maschan A; Balashov D
    J Clin Immunol; 2020 Aug; 40(6):861-871. PubMed ID: 32602054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome.
    Sauer M; Zeidler C; Meissner B; Rehe K; Hanke A; Welte K; Lohse P; Sykora KW
    Bone Marrow Transplant; 2007 Feb; 39(3):143-7. PubMed ID: 17211437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
    Blau IW; Schmidt-Hieber M; Leschinger N; Göldner H; Knauf W; Hopfenmüller W; Thiel E; Blau O
    Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells.
    Cieri N; Greco R; Crucitti L; Morelli M; Giglio F; Levati G; Assanelli A; Carrabba MG; Bellio L; Milani R; Lorentino F; Stanghellini MT; De Freitas T; Marktel S; Bernardi M; Corti C; Vago L; Bonini C; Ciceri F; Peccatori J
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1506-14. PubMed ID: 26001696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Matched Family versus Alternative Donor Hematopoietic Stem Cell Transplantation for Patients with Thalassemia Major: Experience from a Tertiary Referral Center in South India.
    Swaminathan VV; Uppuluri R; Patel S; Ravichandran N; Ramanan KM; Vaidhyanathan L; Ramakrishnan B; Jayakumar I; Raj R
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1326-1331. PubMed ID: 32200123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treosulfan-based conditioning regimen for children and adolescents with hemophagocytic lymphohistiocytosis.
    Lehmberg K; Albert MH; Beier R; Beutel K; Gruhn B; Kröger N; Meisel R; Schulz A; Stachel D; Woessmann W; Janka G; Müller I
    Haematologica; 2014 Jan; 99(1):180-4. PubMed ID: 24162790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
    Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endothelial Activation and Stress Index-Measured Pretransplantation Predicts Transplantation-Related Mortality in Patients with Thalassemia Major Undergoing Transplantation with Thiotepa, Treosulfan, and Fludarabine Conditioning.
    Kulkarni UP; Pai AA; Kavitha ML; Selvarajan S; Lionel S; Devasia AJ; Korula A; Fouzia NA; Sindhuvi E; Abraham A; Srivastava A; Mathews V; George B; Balasubramanian P
    Transplant Cell Ther; 2022 Jul; 28(7):356.e1-356.e6. PubMed ID: 35550442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
    Güngör T; Teira P; Slatter M; Stussi G; Stepensky P; Moshous D; Vermont C; Ahmad I; Shaw PJ; Telles da Cunha JM; Schlegel PG; Hough R; Fasth A; Kentouche K; Gruhn B; Fernandes JF; Lachance S; Bredius R; Resnick IB; Belohradsky BH; Gennery A; Fischer A; Gaspar HB; Schanz U; Seger R; Rentsch K; Veys P; Haddad E; Albert MH; Hassan M;
    Lancet; 2014 Feb; 383(9915):436-48. PubMed ID: 24161820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
    Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Kim CK; Lee KT; Won JH; Hong DS
    Korean J Intern Med; 2016 Jul; 31(4):750-61. PubMed ID: 27017944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.